From bench to bedside: what physicians need to know about endothelial progenitor cells
Matthias Mayr1, David Niederseer, Josef Niebauer
1Department of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University, Salzburg, Austria.
The American Journal of Medicine
|May 25, 2011
Summary
Endothelial progenitor cells (EPCs) have faced challenges in definition and measurement. Recent studies clarify their diagnostic and therapeutic potential for clinicians.
Area of Science:
- Cardiovascular Biology
- Hematology
- Cellular Therapeutics
Background:
- Endothelial progenitor cells (EPCs) were discovered in 1997, sparking significant research and debate.
- Challenges in standardizing EPC detection and measurement have limited clinical understanding and application.
- Previous controversies surrounding EPCs have largely been resolved through extensive research.
Purpose of the Study:
- To provide a comprehensive overview of endothelial progenitor cells (EPCs) for practicing physicians.
- To clarify the measurement, diagnostic, and predictive value of EPCs.
- To discuss the therapeutic potential of EPCs in clinical settings.
Main Methods:
- Review of recent scientific literature and clinical studies on EPCs.
- Analysis of standardized methodologies for EPC detection and quantification.
- Synthesis of data on the clinical relevance of EPCs.
Main Results:
- Standardized methods now facilitate clearer understanding and application of EPCs.
- EPCs demonstrate significant diagnostic and predictive potential in various clinical conditions.
- Emerging therapeutic strategies leverage EPCs for regenerative medicine.
Conclusions:
- EPCs are crucial for endothelial repair and vascular health.
- Standardized approaches enhance the clinical utility of EPCs.
- EPCs hold promise for future cardiovascular therapies.
